Q3 2025 Adaptive Biotechnologies Corp Earnings Call Transcript
Key Points
- Adaptive Biotechnologies Corp (ADPT) achieved a significant milestone with its MRD business becoming cash flow positive, highlighting the strength and scalability of its model.
- MRD revenue grew 52% year over year, driven by robust increases in clinical volume and average selling price (ASP), reflecting expanding clinical utility and broader integration into patient care.
- The company improved its sequencing gross margin by 10 percentage points year over year to 66%, driven by operational efficiencies and cost reductions.
- Adaptive Biotechnologies Corp (ADPT) updated its full-year guidance to reflect higher MRD revenue, lower operating expenses, and reduced annual cash burn, indicating strong financial performance.
- The company achieved several policy wins, including its first large commercial payer coverage in DLBCL and two major payers in CLL, expanding its reimbursement footprint.
- The immune medicine revenue from pharma and academic services decreased to $3.4 million from $5.5 million a year ago, indicating a decline in this segment.
- Despite the positive cash flow in the MRD business, the immune medicine segment reported an adjusted EBITDA deficit, highlighting ongoing financial challenges in this area.
- The company faces emerging competition in the diffuse large B-cell lymphoma (DLBCL) market, which could impact its market position.
- There is uncertainty regarding the FDA's acceptance of MRD as an endpoint for accelerated approval in lymphoid cancers, which could affect future growth prospects.
- The company anticipates some seasonality in Q4 due to holiday ordering, which may impact sequential growth in MRD volumes.
Good day and thank you for standing by.
Welcome to the adaptive biotechnology 3rd quarter earnings conference call.
At this time, all participants are the listen-only mode.
After the speaker's presentation, there will be a question-and-answer session.
To ask a question during the session, you would need to press star 11 on your telephone.
You will then hear an automated me advising your hand is raised to withdraw your question, please press 11 again.
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Karina Calzadilla, Head of Investor Relations.
Please go ahead.
Thank you, Jacinda and good afternoon, everyone.
It's 3rd quarter 2025 earnings conference call.
Earlier today, we issued a press release reporting adaptive financial results for the 3rd quarter of 2025.
The press release is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
